(CIX: WRAL30)  1,170.48  down arrow-1.09  (-0.09 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: Apple)  118.30  up arrow+0.49  (0.42 %)  Updated: 08:10 PM EST, Nov 30 2015
(NY: QUINTILES)  67.99  down arrow-1.27  (-1.83 %)  Updated: 06:40 PM EST, Nov 30 2015
(OP: BASF SE)  82.48  down arrow-0.17  (-0.21 %)  Updated: 05:20 PM EST, Nov 30 2015
(NQ: BioCryst)  10.61  up arrow+0.31  (3.01 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: BioDelivery)  6.13  up arrow+0.1  (1.66 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: CEMP)  31.91  down arrow-0.84  (-2.56 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: Cisco)  27.25  down arrow-0.07  (-0.26 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: Cree)  27.64  up arrow+0.55  (2.03 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: DARA)  0.95  up arrow+0.03  (3.26 %)  Updated: 08:10 PM EST, Nov 30 2015
(NY: EMC)  25.34  down arrow-0.06  (-0.24 %)  Updated: 06:40 PM EST, Nov 30 2015
(NQ: Extreme Networks)  4.42  up arrow+0.08  (1.84 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: Facebook)  104.24  down arrow-1.21  (-1.15 %)  Updated: 08:10 PM EST, Nov 30 2015
(NY: GLAXOSMITHKLINE)  40.51  down arrow-0.45  (-1.1 %)  Updated: 06:40 PM EST, Nov 30 2015
(NQ: Alphabet)  742.60  down arrow-7.66  (-1.02 %)  Updated: 08:10 PM EST, Nov 30 2015
(NY: IBM)  139.42  up arrow+0.96  (0.69 %)  Updated: 06:40 PM EST, Nov 30 2015
(NY: LH)  121.54  down arrow-0.53  (-0.43 %)  Updated: 06:40 PM EST, Nov 30 2015
(OP: Lenovo Group)  21.50  up arrow+0.58  (2.77 %)  Updated: 05:20 PM EST, Nov 30 2015
(NY: MRK)  53.01  down arrow-0.95  (-1.76 %)  Updated: 06:40 PM EST, Nov 30 2015
(NQ: Microsoft)  54.35  up arrow+0.42  (0.78 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: NetApp)  30.66  down arrow-0.03  (-0.1 %)  Updated: 08:10 PM EST, Nov 30 2015
(NY: NOVARTIS AG)  85.24  down arrow-0.6  (-0.7 %)  Updated: 06:40 PM EST, Nov 30 2015
(OP: Novozymes A/S)  48.14  up arrow+0.43  (0.9 %)  Updated: 05:20 PM EST, Nov 30 2015
(NY: Pfizer)  32.77  down arrow-0.02  (-0.06 %)  Updated: 06:40 PM EST, Nov 30 2015
(NQ: Pozen)  7.59  up arrow+0.31  (4.26 %)  Updated: 08:10 PM EST, Nov 30 2015
(NY: Red Hat)  81.41  down arrow-1.09  (-1.32 %)  Updated: 06:40 PM EST, Nov 30 2015
(NQ: BBRY)  7.94  up arrow+0.12  (1.53 %)  Updated: 08:10 PM EST, Nov 30 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  12.91  up arrow+0.09  (0.7 %)  Updated: 08:10 PM EST, Nov 30 2015

Posts tagged “PPD”

Updated April 10

Premium Lock Validic's fast growth; LinkedIn's $1.5B buy; new PPD joint venture; Liquidia demos its tech; Zynga founder returns

Bulldog In today's Bulldog wrapup of technology and life science news: Startup Validic reports fast growth; LinkedIn's big acquisition; PPD forms a joint venture in Japan; Liquidia demos at vaccine congress; and Zynga's founder returns as CEO.

September 26, 2014

Premium Lock PPD buys remaining interest in firm it has owned since 2010

PPD Wilmington-based PPD, which has a large presence in the Triangle, on Thursday bought the remaining minority interest in a Massachusetts firm which it originally acquired in 2010.

April 29, 2014

Premium Lock From our archives: The Fred Eshelman saga includes one-person startup at PPD to Wilmington's Walk of Fame and now a $1.1B sale of Furiex

Fred Eshelman Looking back at Fred Eshelman's career: A 2009 blog post recapped a tumultuous year for Eshelman and PPD in which the company's stock was hammered and he stepped down as CEO to become executive chairman. But the year was capped with a salute. From there, Eshelman has continued to make headlines.

August 28, 2013

Premium Lock PPD acquires Acurian to improve recruitment, retention in clinical trials

David Simmons M&A dealmaking in the contract research organization sector strikes again as PPD buys a company. Read how the Acurian acquisition helps Wilmington-based PPD.

November 30, 2012

Premium Lock PPD lands top technology honor in life science awards

PPD PPD's 3D technology for global training in clinical trials receives the Best Technological Development in Clinical Trials honor from Scrip, an international life science media and technology firm.

November 21, 2012

Premium Lock Oxygen Biotherapeutics picks PPD to run clinical trial

PPD Oxygen Biotherapeutics picks PPD as the contract research organization to run a Phase 2 clinical trial on a proposed treatment for traumatic brain injury.

October 25, 2012

Premium Lock $9M in new funding positions Clinipace for more deals

Clinical research organization Clinipace's fundraising haul today of $9 million puts it in a position to do more of what the Morrisville company has been doing in over the last two years - finding and acquiring companies.

Clinipace's website touts its growing reach, expertise Clinipace's website touts its growing reach, expertise

September 17, 2012

Premium Lock SAS customer win; PPD allergy deal; new ATTUS service; DARA license deal; Chemring $49M contract

Bulldog Inside the Bulldog Blog: SAS wins XL Group as Visual Analytics customer; PPD to work with Europeans on allergies; ATTUS expands compliance services; DARA licenses topical gel; Chemring wins big defense contract.

Updated September 13, 2012

Premium Lock Quintiles ranks No. 6 in InformationWeek '500'

Lowe's, PPD, SAS, Bank of America and Martin Marietta also crack the top 200 in the annual ranking of information technology trend-setters as selected by InformationWeek magazine.

IW 500 IW 500

May 23, 2012

Premium Lock PPD hires Pfizer executive as its new CEO

David Simmons David Simmons will take over as the leader of the Wilmington-based life science services company on June 4. PPD has been without a CEO since December.

March 2, 2012

Premium Lock Raleigh-based INC Research tops life science service firm survey

INC Research  The study by Cary-based Industry Standard Research is possibly the most comprehensive measure of what pharmaceutical companies think about contract research organizations.

January 30, 2012

Premium Lock Drug partnerships: Not all positive, not all negative

Pozen CEO says there are lessons to be learned from its past partnership deals as the Chapel Hill firm seeks another one.

Pozen CEO John Plachetka  Pozen CEO John Plachetka

January 12, 2012

Premium Lock Life science service sector to rebound, report says

Biotech & Life Science "We expect growth in the CRO industry to continue accelerating into 2012 and the rise of the strategic partnership model should concentrate these benefits in the hands of a select group of narrow-moat providers," says a Morningstar analyst.

Updated December 26, 2011

Premium Lock What's on shopping list for CROs in the new year?

Biotech & Life Science Partners, M&A possibilities, sites in Asia, private equity investments and more consulting expertise are appealing items on the want lists for contract research organizations.

Updated December 14, 2011

Premium Lock PPD CEO steps down; founder Eshelman remains a senior advisor

Ray Hill PPD CEO Ray Hill has stepped down from the clinical research organization a week after PPD's acquisition by The Carlyle Group and Hellman & Friedman was finalized. He departs with a $3 million severance package for running the company since September.

December 5, 2011

Premium Lock Private equity firms close on $3.9B PPD deal

PPD The private equity firms announced the completion of the all-cash deal for the clinical research organization Monday. The close follows an approval vote from shareholders last week.

December 2, 2011

Premium Lock PPD deal includes $21M in 'golden parachutes' for top execs

Even as shareholders approve the $3.9 billion sale of the contract research organization to private equity groups, the future role of PPD management remains unclear.

Fred Eshelman   Fred Eshelman

Techwire Inside Partners
The Skinny: A Blog by Rick Smith